Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460100 | 0.83 | NPC1 (0.45) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL2064455 | 0.83 | NPC1 (0.58) | NPC1RAB9AALDH1A1MAPTPOLB | |
| SCHEMBL7290567 | 0.83 | CA1 (0.54) | NPC1RAB9AALDH1A1MAPTCA12 | |
| SCHEMBL14735749 | 0.82 | NPC1 (0.58) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL841978 | 0.81 | ESR2 (0.50) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL246263 | 0.81 | HDAC3 (0.66) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL10796669 | 0.81 | HAO1 (0.46) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL3833913 | 0.81 | LMNA (0.50) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL7290231 | 0.81 | GSK3B (0.41) | ESR2NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL20135229 | 0.81 | MAPT (0.62) | ESR2NPC1RAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019231-A | Preparation method of p-methoxyethylphenol | 常州瑞明药业有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-107382683-A | A kind of synthetic method for preparing Metoprolol intermediate | 荆门医药工业技术研究院 | 2017-11-24 | — | — | CN | claimed |
| US-5107034-A | Bromination of 4-hydroxyacetophenone, treating with methoxide to produce alpha-methoxy-4-hydroxyacetophenone, reduction | HOECHST CELANESE CORPORATION (US) | 1992-04-21 | — | — | US | claimed |
| EP-0449602-A1 | Method for producing 4-(2'-methoxyethyl) phenol | HOECHST CELANESE CORPORATION (US) | 1991-10-02 | — | — | EP | claimed |
| EP-0041295-B1 | PROCESS FOR THE PREPARATION OF 1-ISOPROPYLAMINO-3-(4-(2-METHOXY-ETHYL)-PHENOXY)-2-PROPANOL | Aktiebolaget Hässle (SE) | 1984-01-04 | — | — | EP | claimed |
| EP-0041295-A1 | Process for the preparation of 1-isopropylamino-3-(4-(2-methoxy-ethyl)-phenoxy)-2-propanol | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | claimed |
| JP-4221334-A | — | — | None | — | — | JP | disclosed |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025104230-A1 | BENZOXAZOLES AS MODULATORS OF IL-17A | SANOFI (FR) | 2025-05-22 | — | — | WO | disclosed |
| CN-119019231-A | Preparation method of p-methoxyethylphenol | 常州瑞明药业有限公司 | 2024-11-26 | — | — | CN | disclosed |
| WO-2024115926-A1 | FORMULATION COMPRISING APOCYNIN AND PAEONOL | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2024-06-06 | — | — | WO | disclosed |
| CN-116999417-A | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RES & DEVELOPMENT LTD (GB) | 2023-10-19 | — | — | US | disclosed |
| EP-0113236-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES-PYRAZINES, AND -TRIAZINES | ELI LILLY AND COMPANY (US) | 1987-04-22 | — | — | EP | disclosed |
| US-4636502-A | Methods of producing a positive inotropic effect or vasodilation by administration of 2-phenyl imidazo pyrimidines and pyrazines | ELI LILLY AND COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| US-4537889-A | PHENYL SUBSTITUTED IMIDAZO COMPOUNDS | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0113236-A1 | Substituted imidazopyrimidines-pyrazines, and -triazines | ELI LILLY AND COMPANY (US) | 1984-07-11 | — | — | EP | disclosed |
| EP-0041295-B1 | PROCESS FOR THE PREPARATION OF 1-ISOPROPYLAMINO-3-(4-(2-METHOXY-ETHYL)-PHENOXY)-2-PROPANOL | Aktiebolaget Hässle (SE) | 1984-01-04 | — | — | EP | disclosed |
| EP-0041295-A1 | Process for the preparation of 1-isopropylamino-3-(4-(2-methoxy-ethyl)-phenoxy)-2-propanol | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | disclosed |
| EP-0041295-A1 | Process for the preparation of 1-isopropylamino-3-(4-(2-methoxy-ethyl)-phenoxy)-2-propanol | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | LPL, PNLIP, LPO | ESR2 4024/4885NPC1 1163/4885RAB9A 4416/4885 |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | IL17A, IL2, IL36G | ESR2 360/4885NPC1 461/4885RAB9A 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.